Abstract
BACKGROUND Safe and effective antidepressant deprescribing strategies are needed in general practice where most antidepressant prescribing occurs.
METHODS We conducted a pragmatic, cluster-randomised controlled trial in general practice to test invitation to general practitioner (GP) review combined with resources to inform shared decision-making and guide hyperbolic tapering for stopping antidepressants compared to usual care. Adults taking antidepressants for longer than 12 months were recruited from 26 Australian GP practices between March 2023 and November 2024, irrespective of their intention to stop or depression or anxiety symptom scores. The primary outcome was cessation at 12 months. Secondary outcomes included cessation at 6 months, and >75% dose reduction and depression, anxiety and withdrawal symptom scores at 6 and 12 months.
RESULTS Overall, 483 patients were randomised. Mean age was 50 years; 73% were women; mean duration of antidepressant use was 14.1 years. Cessation at 12 months was observed in 32 of 215 (14.9%) intervention and 16 of 187 (8.6%) usual care patients (odds ratio (OR) = 1.95 [95%CI, 1.00 to 3.81]; p=0.050). Cessation at 6 months was observed in 11.7% intervention vs 4.8% usual care (OR = 2.68; 95%CI, 1.18 to 6.05), and >75% dose reduction at 12 months in 19.6% intervention vs 9.9% usual care (OR = 2.28; 95%CI, 1.20 to 4.31). Symptom scores were similar between groups. No adverse events were attributable to the intervention.
CONCLUSIONS In general practice, invitation to GP antidepressant review combined with information and guidance on hyperbolic tapering can support cessation or dose reduction without causing adverse effects or relapse. Absolute cessation rates were modest but still meaningful given the high prevalence of long-term antidepressant use.
TRIAL REGISTRATION ANZCT registry identifier, ACTRN12622001379707p.
WHAT IS ALREADY KNOWN ON THIS TOPIC
Long-term (>12 months) antidepressant use is common in primary care, despite being potentially unnecessary and associated with increased risk of falls, sexual dysfunction, weight gain and diabetes.
Lack of recognition and management of antidepressant withdrawal symptoms and fear of relapse are important drivers of long-term use.
Safe and effective antidepressant deprescribing strategies are needed in primary care where most antidepressant prescribing occurs.
WHAT THIS STUDY ADDS
The RELEASE intervention comprised invitation to GP antidepressant review combined with patient-centred resources to inform shared decision-making and guide hyperbolic tapering.
The intervention increased cessation or dose reduction, without increasing adverse effects including relapse, in a challenging population with mean duration of antidepressant therapy of 14.1 years and no intention to stop.
Competing Interest Statement
Katharine Wallis declares receiving reimbursement of travel expenses to attend the European College of Neuropsychopharmacology congress 2025. Joanna Moncrieff declares grants from the National Institute for Health Research, Royalties for books about psychiatric drugs, and being co-chairperson of the Critical Psychiatry Network. Mark Horowitz declares Royalties from the Maudsley Deprescribing Guidelines: Antidepressants, Benzodiazepines, Gabapentinoids and Z-drugs, consulting fees and stock from Outro Health a digital clinic in the US that helps patients to safely stop no longer needed antidepressants, Honoraria from universities and NHS Trusts for talks on deprescribing, and expenses for attending academic conferences.
Clinical Trial
ANZCT registry identifier, ACTRN12622001379707p.
Clinical Protocols
https://link.springer.com/article/10.1186/s13063-023-07646-w
https://www.medrxiv.org/content/10.1101/2024.10.08.24314879v1.full
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study received approval from The University of Queensland Human Research Ethics Committee (2022/HE001667).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors
Funder Information Declared
